PharmaNet system dramatically reduced inappropriate prescriptions of potentially addictive drugs

September 4, 2012

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

The study found that PharmaNet, a real-time prescription system implemented in BC pharmacies in July 1995, reduced potentially inappropriate prescriptions for opioids and benzodiazepines in two groups of patients—those on social assistance and seniors. The reductions ranged from about one-third (33%) to one-half (49%) depending on the drug and patient group.

"Our study demonstrates that a system like PharmaNet can help reduce the potentially inappropriate prescribing of medications that are prone to misuse," said lead author Colin Dormuth of the Therapeutics Initiative at the University of British Columbia. "In the five-year period of our study, the reduction in inappropriate refills was dramatic and sustained after the implementation of PharmaNet."

The PharmaNet system allows BC pharmacists to view the most recent 14 months of a patient's medication use regardless of which physician prescribed the drugs or which pharmacy dispensed them. The system enables pharmacists to identify potentially harmful drug interactions, accidental duplications in therapy or potential prescription .

Researchers tracked "potentially inappropriate" prescriptions for opioids and benzodiazepines in BC, defined as a second prescription for the same drug issued by a different doctor and a different pharmacy within 7 days of a previous prescription for at least 30 tablets.

Benzodiazepines and are that are prone to misuse and addiction in some patients. Benzodiazepines include sedatives and anti-anxiety drugs such as diazepam, lorazepam and others, whereas are taken for pain relief and include morphine, codeine, oxycodone and other drugs.

Most provinces have now adopted either a system allowing the to view a patient's up-to-date medication history at the time of dispensing a medication or a real-time monitoring program specifically aimed at monitoring prescription drugs prone to misuse. Ontario adopted the latter approach in establishing its Narcotics Monitoring System earlier this year.

"Centralized drug information systems and monitoring programs are critical to help ensure these medications are used appropriately," observes coauthor David Juurlink, Head of Clinical Pharmacology and Toxicology at Toronto's Sunnybrook Health Sciences Centre and a scientist at the Institute for Clinical and Evaluative Sciences (ICES).

The study covered the period from Jan. 1, 1993 to Dec. 31, 1997—the 5-year period flanking the program's implementation. Because comprehensive data was available for people aged 65 years and over and patients receiving social assistance, the study focused on these two groups of patients.

Explore further: Harmful patterns of painkiller prescriptions seen among methadone patients

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.120465

Related Stories

Harmful patterns of painkiller prescriptions seen among methadone patients

November 28, 2011
A new study has shown harmful prescription patterns of powerful painkillers among a substantial number of Ontario patients who received methadone therapy to treat their opioid addiction.

Opioids linked to higher risk of pneumonia in older adults

September 22, 2011
Opioids -- a class of medicines commonly given for pain -- were associated with a higher risk of pneumonia in a study of 3,061 adults, aged 65 to 94, e-published in advance of publication in the Journal of the American Geriatrics ...

Black patients more likely to be monitored for prescription drug abuse

May 10, 2011
(Medical Xpress) -- Despite studies that show that whites are more likely than blacks to misuse prescription pain medications, a new study reveals that blacks are significantly more likely than whites to be checked for potential ...

Study shows pharmacies' software systems miss potentially dangerous interactions

May 17, 2011
A study conducted at the University of Arizona College of Pharmacy found that only 28 percent of pharmacies' clinical decision support software systems – the computer programs that are in place to alert pharmacists to ...

Drexel study: Misuse of pain medication is pathway to high-risk behaviors

July 22, 2011
A new study by researchers at Drexel University's School of Public Health suggests that abuse of prescription painkillers may be an important gateway to the use of injected drugs such as heroin, among people with a history ...

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.